- 701studies on this subject, of 27,380 in the library
- 685peer-reviewed
- 1999–2026years published
- 49median usefulness score out of 100
These counts and lists are worked out from the library itself each time the page loads. A score rates how much weight a study can bear — its design, journal, evidence and recency — not whether its result is good news. How we score a study.
The 20 highest-scoring studies
-
Addition of a non-immersive virtual reality component to treadmill training to reduce fall risk in older adults (V-TIME): a randomised controlled trial
In older adults at high risk of falls, treadmill training combined with a non-immersive virtual reality component reduced fall rates more than treadmill training alone. This is about preventing falls, not about treating, curing, or preventing Alzheimer's disease.
-
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
In this large multicenter PET study, cognitively unimpaired people who were positive for both amyloid and tau had a substantially increased risk of progressing to mild cognitive impairment compared with those negative for both. This shows these PET markers can identify high-risk individuals, but it does not test any treatment or prevention.
-
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
This 2009 study repeated PIB and MRI imaging in people who were cognitively normal, had mild cognitive impairment or had Alzheimer's disease, to learn the order in which disease changes happen. PIB retention rose by a small amount each year in all participants (median 0.042 ratio units/year, P < 0.001), and the yearly rise did not differ between the three groups (P = 0.90); the authors concluded that "significant plaque deposition occurs prior to clinical decline." It is an observational imaging study: it tested no treatment, our record does not include its MRI results, and timing alone does not show that plaque causes the decline.
-
Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease
In the Swedish BioFINDER study, plasma p-tau217 increased over time in people with preclinical and prodromal Alzheimer's disease and in those with mild cognitive impairment who later converted to dementia, but it did not change in amyloid-negative participants or non-converters. This suggests p-tau217 could be used to monitor disease progression, but it is not a treatment, cure, or prevention.
-
Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis of cohort studies
This review of 60 studies found that several factors, including abnormal cerebrospinal fluid proteins, brain shrinkage in certain regions, and the APOEε4 gene, were linked to a higher risk of progressing from mild cognitive impairment to Alzheimer's disease. These markers may help predict who will develop the disease, but the review does not show that any treatment targeting them can prevent it.
-
Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment
In elderly people with mild cognitive impairment, high-dose B-vitamin treatment slowed shrinkage of brain regions vulnerable to Alzheimer's disease, and this benefit was confined to those with high homocysteine levels. This suggests that lowering homocysteine with B vitamins may slow brain atrophy and cognitive decline in this specific group, though it does not show the disease can be cured or prevented.
-
Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial
In this randomized controlled trial of 51 people with mild cognitive impairment or early Alzheimer's dementia, an intensive multidomain lifestyle intervention was compared with usual care over 20 weeks. The summary states that comprehensive lifestyle changes may significantly improve cognition and function, but this is a single small trial and does not establish a cure or prevention.
-
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study
In a double-blind trial of 1,018 people with mild cognitive impairment followed for up to four years, 17.3% of those on rivastigmine and 21.4% on placebo were diagnosed with Alzheimer's disease. The difference was not statistically significant (hazard ratio 0.85, 95% CI 0.64–1.12), and cognitive test scores did not differ either. The authors found no significant safety concerns. They also noted that far fewer participants progressed to Alzheimer's than predicted.
-
Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
This review of five trials with 879 participants found no significant effect of three years of vitamin E supplementation on overall cognitive function or other outcomes, and none of the trials reported dementia incidence. The evidence on overall cognitive function was of very low quality.
-
Cholinesterase inhibitors for mild cognitive impairment
This review of nine studies found cholinesterase inhibitors had essentially no effect on cognitive test scores in people with mild cognitive impairment and were linked to significantly more adverse events. The weak evidence of reduced conversion was outweighed by the increased risk of side effects.
-
Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures
A combination of plasma phospho-tau, brief cognitive tests and APOE genotype predicted progression to Alzheimer's dementia more accurately than memory clinic physicians' clinical predictions. This suggests a blood-based tool could improve prediction of who will develop dementia, though it is a prediction model and not a treatment.
-
Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients
This meta-analysis found that shrinkage in the entorhinal area and hippocampus, and reduced metabolism in certain parietal regions, were the most reliable imaging signs for predicting progression from mild cognitive impairment to Alzheimer's disease. These markers may aid early diagnosis, but the study does not provide a treatment.
-
Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment
This review of 33 studies with 3,935 participants assessed the accuracy of structural MRI for early diagnosis of Alzheimer's disease dementia in people with mild cognitive impairment, finding no difference in total hippocampal volume accuracy by follow-up duration or age. It addresses diagnostic accuracy only, not treatment, cure, or prevention.
-
Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship
In amyloid-positive participants, greater cognitive reserve based on gray matter volume was linked to lower risk of progressing to mild cognitive impairment or Alzheimer's dementia. However, once symptoms appeared, higher cognitive reserve was also associated with faster subsequent decline, so its role in progression is complex.
-
The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects
This longitudinal PET study found that the rate of tau accumulation was greater in females and younger amyloid-positive individuals, while amyloid accumulation was greater in APOE ε4 carriers and older individuals. The authors say these findings are important for designing clinical trials and understanding factors linked to faster tau aggregation.
-
Computerised cognitive training for preventing dementia in people with mild cognitive impairment
This review of eight randomized trials with 660 participants found very low-quality evidence, and no trial reported data on incident dementia, so no conclusions could be drawn about whether computerized cognitive training prevents dementia. There was low-quality evidence suggesting probably no effect on speed of processing, verbal fluency or quality of life, so this review does not support computerized cognitive training as a way to prevent dementia.
-
Pharmacological and non-pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: A systematic review
This systematic review of 16 studies with 1,056 participants found that adapted cognitive behavioural therapy for insomnia and a structured limbs exercise programme each significantly improved sleep quality, and that suvorexant and melatonin improved certain sleep measures in small studies. The review addresses sleep interventions in mild cognitive impairment and mild dementia, but does not show that improving sleep prevents or slows Alzheimer's disease.
-
Longitudinal pattern of regional brain volume change differentiates normal aging from MCI
In this longitudinal study, all brain volumes declined with normal aging, but mild cognitive impairment was associated with a distinct pattern of greater volume loss in specific regions. This suggests imaging can help distinguish MCI from normal aging, but it is an observational finding with no treatment tested.
-
Late-life depression, mild cognitive impairment, and dementia
In a multiethnic community cohort, baseline depression was associated with a higher risk of incident dementia but not incident mild cognitive impairment, and people with both mild cognitive impairment and depression had a higher risk of progressing to dementia, especially vascular dementia but not Alzheimer's disease. This identifies depression as a risk marker, but it does not show that treating depression prevents or cures Alzheimer's disease.
-
Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy
Donepezil plus antidepressant therapy temporarily improved global cognition in older adults with depression, but the effect sizes were small. In a post hoc subgroup of 57 participants with mild cognitive impairment, fewer on donepezil converted to dementia than on placebo, but this was a secondary analysis of a small group and needs confirmation.
See all 701 studies in Mild cognitive impairment, with filters →
Newest additions on this subject
- Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment
- Neuroinflammation is an early pathological process in a mouse model of prodromal Parkinsons disease
- Cognitive Impairment during Migraine Attacks: An Analysis from the American Registry for Migraine Research (ARMR)
- Neuro-JEPA: Building and Evaluating Health-System Scale Neuroimaging Foundation Models with Mixture of Experts
- Limbic Vulnerability Characterises REM Sleep Behaviour Disorder Across Prodromal and Established Lewy Body Disease
- Cross-Tissue Inflammatory Convergence Supports a Putative Muscle–Brain Axis in Alzheimer’s Disease
- Multilingualism and ageing: Cognitive and affective trajectories in the Australian Longitudinal Study of Ageing
- Explainable machine learning identifies predictors for postural instability and cognitive impairment in early Parkinson’s Disease
- Evaluating Patient Representation Strategies for Early Prediction of Alzheimer’s Disease and Related Dementias from Longitudinal EHRs
- Dementia Language Models: a generalizable and controllable representation of cognitive impairment
All 701 studies in Mild cognitive impairment, newest first →
What the library holds on this subject
By review status
| Status | Studies |
|---|---|
| Peer-reviewed | 685 |
| Preprint — not yet peer-reviewed | 16 |
By strength of evidence
| Rated in our summary | Studies |
|---|---|
| low | 414 |
| moderate | 232 |
| high | 51 |
| not rated | 4 |
Most frequent journals
| Journal | Studies |
|---|---|
| Neurology | 32 |
| Brain : a journal of neurology | 31 |
| Alzheimer's & dementia : the journal of the Alzheimer's Association | 28 |
| Journal of Alzheimer's disease : JAD | 26 |
| Alzheimer s & Dementia | 24 |
| NeuroImage | 22 |
| Neurobiology of aging | 19 |
| Journal of Alzheimer s Disease | 14 |
| Alzheimer's research & therapy | 11 |
| Archives of neurology | 11 |
Studies by year published
| Year | Studies | Bar |
|---|---|---|
| 2026 | 52 | |
| 2025 | 146 | |
| 2024 | 1 | |
| 2023 | 5 | |
| 2022 | 9 | |
| 2021 | 17 | |
| 2020 | 23 | |
| 2019 | 26 | |
| 2018 | 23 | |
| 2017 | 25 | |
| 2016 | 32 | |
| 2015 | 42 | |
| 2014 | 23 | |
| 2013 | 28 | |
| 2012 | 31 | |
| 2011 | 29 | |
| 2010 | 34 | |
| 2009 | 30 | |
| 2008 | 25 | |
| 2007 | 31 | |
| 2006 | 23 | |
| 2005 | 13 | |
| 2004 | 7 | |
| 2003 | 7 | |
| 2002 | 10 | |
| 2001 | 5 | |
| 2000 | 1 | |
| 1999 | 3 |
Counts the 701 studies with a usable publication date. The library is a large sample of published work, not a complete index, so these counts describe the library, not the whole field.
Other subjects in the library
- Getting a diagnosis
- Biomarkers
- Clinical trials
- Prevention and risk
- Caregiving
- How common it is
- Costs and economics
- Genetics
- Laboratory science
- Disease mechanisms
- Vascular contributions
- Prevention trials
- Clinical safety
- Health systems and care delivery
- End-of-life care
- Risk factors
- Digital health tools
- Treatments
- Disparities
- Risk genes beyond APOE
- Brain scans and imaging
- TREM2 and immune genetics
- Cognitive tests and assessment
- Lewy body dementia
- Down syndrome and Alzheimer's
- Long-term cohort studies
- Inflammation and the immune system
- Tau biomarkers
- Brain tissue and pathology
- Drug development
- Hippocampus size on brain scans